The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
INP Cytoskeleton and Neurophysiopathology team, together with several leading groups in tau biology, has participated in a joint review of the field that just came out in Acta Neuropathologica Communications. This review summarizes the recent breakthroughs in deciphering the molecular structures, both physiological and pathological, of the elusive protein tau.
Read online (open access) : https://link.springer.com/article/10.1186/s40478-019-0682-x
Title : The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?
The last work of team 9 "Tau regulates the microtubule-dependent migration of glioblastoma cells via Rho-ROCK signaling pathway" is now published in J. cell. Science. This work identifies for the first time the role and mechanisms implicating the tau protein in the invasion processes of glioblastomas, very aggressive brain tumors. This work highlights the role of the Tau protein as a common target between cancers and neurodegeneration.
Professor of Biophysics and Biomathematics at the Faculty of Pharmacy of Marseille, Hervé Kovacic is elected for a six-year term. Section CNU 85 manages the qualifications, promotions and bonuses of teacher-researchers specializing in physicochemical sciences and applied engineering in health. Doctor Pascale Barbier, also from team 9 of INP has been nominated as a member of the same CNU section.
Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.
On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students were invited to present their work.
It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.
The first conference entitled “Alzheimer’s disease, fears and hopes” was given at the meeting of the management boards of the french Vaincre l’Alzheimer and the german Alzheimer Forschung Initiative foundations that was held on November 16th 2018 at the Novotel Hotel Marseille Vieux Port.
The second conference, in the context of the Conferences Cycle of the Institute of Neurosciences of the University of Barcelona, was entitled “ Membrane type-matrix metalloproteinases are newcomers to the Alzheimer’s field ” ans was held on November 20th at the School of Pharmacy of the University of Barcelona.
The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R). Our data unveil new mechanistic insights supporting the pro-amyloidogenic role of MT1-MMP based on APP processing and trafficking, and reinforces the idea that MT1-MMP may become a new potential therapeutic target in Alzheimer’s disease.
In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.
Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".
Subsequently she was interviewed by :
- France 3 (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ;
- Provence Azur (18/11/2019) ;
- 20 Minutes Marseille (18/11/2019)
- La Provence
Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.
The leading peer-reviewed journal dedicated to understanding of the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease, exploring key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics.
For more information, head to the ARS website.
Congratulations to all the CNRS team for running the Marseille-Cassis race two weekends ago, and especially to Claude Villard (7th from the left, top row), INP team 9 and PINT facility member who ran this semi-marathon in 1 hour and 48 minutes.
Next year, let's make a whole INP team (as usual, the race will take place on the last Sunday of October)!
For more information, head to the race's official website.
During the NeuroStories event, held on Monday October 7 at the Faculty of Medicine, Anne-Marie François Bellan gave a remarkable stand up on how our body vibrates to the rhythm of internal chronometers called circadian clocks. She also explained how the molecular clock uses small corpuscles and cell space to make our genes rhythm.
Click on the news to see the video of her brilliant speech.
The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.
During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat